Contezolid (Youxitai; MRX-I) is an orally bioavailable oxazolidinone-based antibacterial agent potentially for the treatment of acute bacterial skin. It acts as a protein synthesis inhibitor. Contezolid (Youxitai) was developed by Shanghai MicuRx Pharmaceuticals to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). As of 2021, it has been approved in China as an antibiotic.

纯度：≥98%

CAS：1112968-42-9